EXACT Sciences Corp

Type: Company
Name: EXACT Sciences Corp
Nationality: United States
Web Address: http://www.exactsciences.com/
First reported 3 hours ago - Updated 51 mins ago - 1 reports

Exact Sciences Corporation (EXAS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new company profile report

Exact Sciences Corporation (Exact) is a molecular diagnostics company that focuses on the early detection and prevention of colorectal cancer. The Company's proprietary non-invasive stool-based deoxyribonucleic acid (sDNA) screening technology is used ... [Published TransWorldNews - 3 hours ago]
First reported May 19 2013 - Updated May 19 2013 - 1 reports
Keryx Biopharmaceuticals Inc
Keryx Biopharmaceuticals Inc

BioTech Reports Show Volatile and Profitable Market

) San Francisco, CA -- Investing in Biotech has been a difficult sustainable proposition since the start. It can be difficult to find multiple worthwhile stocks in the sector that can be seen as overall worthwhile long term investment. Still, biotechs ... [Published EMAILWIRE.com - May 19 2013]
First reported May 19 2013 - Updated May 19 2013 - 1 reports

Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com

These molecular diagnostics market reports provide a comprehensive analysis for US, UK, Spain, Japan, Italy, Germany and France: Major issues pertaining to the molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, ... [Published Zecco - May 19 2013]
First reported May 18 2013 - Updated May 18 2013 - 1 reports

Post Earnings Update: Exact Sciences...

When Exact Sciences (NASDAQ:EXAS) reported earnings two weeks ago on May 1st, 2013, analysts, on average, expected the company to report a loss of $0.20 on sales of $1.0 million. The company actually reported a loss of $0.17 per share on sales of $1.0 ... [Published Financial News Network online - May 18 2013]
First reported May 16 2013 - Updated May 17 2013 - 1 reports
EXACT Sciences Corp
EXACT Sciences Corp

Exact Sciences Shares Climbing Higher, Up 1.5%

(Financial News Network On) One of today's notable stocks on the rise is Exact Sciences (NASDAQ:EXAS), up 1.5% to $10.69. The Dow Jones Industrial Average is now trading fractionally higher to 15,277 and the S&P is trading fractionally lower to 1,657. ... [Published Individual.com - May 16 2013]
First reported May 17 2013 - Updated May 17 2013 - 1 reports
InterMune Inc
InterMune Inc

Shares of InterMune Rank the Highest in...

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the potential to outperform.InterMune (NASDAQ:ITMN) ... [Published Financial News Network online - May 17 2013]
First reported May 14 2013 - Updated May 14 2013 - 1 reports
United Nations
United Nations

Cuban Schools Analyze Development of UN Projects

SANTA CLARA, Cuba, May 14 (acn) The development of programs linked to peace and to the struggle against hunger is analyzed in the National Seminar of Cuban Schools Associated to the United Nations Education, Science and Culture Organization (UNESCO), ... [Published Agencia de Informacion Nacional - May 14 2013]
First reported May 13 2013 - Updated May 13 2013 - 1 reports

Buyers Accumulate Shares of Exact...

Up 1.5% to $10.07, Exact Sciences (NASDAQ:EXAS), is one of today's notable movers. The S&P is currently trading fractionally lower to 1,632 and the Dow Jones Industrial Average is trading fractionally lower to 15,091.EXACT Sciences Corporation is an applied ... [Published Financial News Network online - May 13 2013]
First reported May 08 2013 - Updated May 08 2013 - 1 reports

Exact Sciences to Take Part in May Investor Conferences [Man. . .

Exact Sciences to Take Part in May Investor Conferences [Manufacturing Close - Up]ProQuest Information & LearningExact Sciences Corp. announced that Kevin T. Conroy, the company's president and chief executive, will present at three investor conferences ... [Published Equities.com - May 08 2013]
First reported May 01 2013 - Updated May 01 2013 - 2 reports

Exact Sciences Earnings: Here’s Why Investors are Not Happy Now

Exact Sciences Corporation ( NASDAQ:EXAS ) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 2.57%.Markets are ... [Published Wall St. Cheat Sheet - May 01 2013]
First reported Apr 24 2013 - Updated Apr 24 2013 - 2 reports

Top-Line Data Show Exact Sciences Cologuard Test Demo. . .

Top-Line Data Show Exact Sciences' Cologuard Test Demonstrates 92 Percent Sensitivity in the Detection of Colorectal CancerExact Sciences Corp.NewsRx.comBy a News Reporter-Staff News Editor at Clinical Trials Week -- Sensitivity measures a test's ability ... [Published Equities.com - Apr 24 2013]
First reported Apr 22 2013 - Updated Apr 23 2013 - 3 reports

DNA test shows promise for noninvasive colorectal cancer detection

Exact Sciences has developed a stool-based screening test that detected 92 percent of cancers found on colonoscopy and 42 percent of precancerous polyps. The results fell shy of the company’s goal of a 50 percent polyp detection rate, according to an ... [Published HealthImaging - Apr 23 2013]

Quotes

...citing results from a recent clinical trial that suggest the stool-based test can detect 65 percent of polyps measuring 2 centimeters or more. "Colon cancer is the most preventable yet least prevented cancer. ... There is a significant need for something different."
Colon Cancer Among 'Least Prevented' [Published ABC News - May 11 2013]
...Jan Groen, CEO of MDxHealth. "We are extremely pleased with the growing momentum of our commercialization efforts, augmented by the recent expansion of the sales force and the publication of our clinical validation study in the Journal of Urology earlier this year. We believe the increased awareness of ConfirmMDx among urologists will result in continued adoption by the urology community and drive positive coverage decisions by payors."
MDxHealth Provides First Quarter 2013 Business Update [Published Reuters - May 07 2013]
...pivotal clinical trial and announced strong preliminary, top-line trial results," said Kevin T Conroy, the company's president and chief executive. "We are extremely pleased with Cologuard's achievement of superiority to the fecal immunochemical test or FIT for both cancer and pre-cancer sensitivity. We intend to seek FDA approval for claims of superiority over the FIT test for both cancer and pre-cancerous polyp detection."
Exact Sciences Releases 1Q 2013 Financial Results, Elects New Board Member [Published Individual.com - May 06 2013]
...(NASDAQCM: ORMP), a developer of oral delivery systems of drugs currently administered by injection, announced today that its article titled, "Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled Type 1 diabetes: a pilot study" has been published in PLOS ONE, an international, peer-reviewed, open-access journal which covers primary scientific and medical research
Shire's Vyvanse Approved in US; Raptor's PROCYSBI Receives FDA Approval [Published BioMedReports - May 02 2013]

More Content

All (166) | News (116) | Reports (9) | Blogs (13) | Audio/Video (0) | Fact Sheets (0) | Press Releases (28)
sort by: Date | Relevance
Exact Sciences Corporation (EXAS) - Pharmaceuti... [Published TransWorldNews - 3 hours ago]
BioTech Reports Show Volatile and Profitable Ma... [Published EMAILWIRE.com - May 19 2013]
Molecular Diagnostics Market - US, UK, Spain, J... [Published Zecco - May 19 2013]
Post Earnings Update: Exact Sciences... [Published Financial News Network online - May 18 2013]
Shares of InterMune Rank the Highest in... [Published Financial News Network online - May 17 2013]
WisBusiness: The Show - WellIntel CEO Marian Si... [Published Wis Business.com - May 16 2013]
Exact Sciences Shares Climbing Higher, Up 1.5% [Published Individual.com - May 16 2013]
Cuban Schools Analyze Development of UN Projects [Published Agencia de Informacion Nacional - May 14 2013]
Buyers Accumulate Shares of Exact... [Published Financial News Network online - May 13 2013]
Jefferies Stocks to Buy: Big Gains in Life Scie... [Published 24/7 Wall St - May 13 2013]
Colon Cancer Among 'Least Prevented' [Published ABC News - May 11 2013]
Registrations for cooperation programs with the... [Published Noodls - May 09 2013]
Fulbright awardee [Published University of Delaware - May 08 2013]
Arena Pharmaceuticals has the Best... [Published Financial News Network online - May 08 2013]
Exact Sciences to Take Part in May Investor Con... [Published Equities.com - May 08 2013]
MDxHealth Provides First Quarter 2013 Business ... [Published Reuters - May 07 2013]
Borderline Views: Investing in the humanities [Published Jerusalem Post - May 06 2013]
EXACT Sciences Corporation (EXAS) to Participat... [Published BioSpace - May 06 2013]
Exact Sciences Releases 1Q 2013 Financial Resul... [Published Individual.com - May 06 2013]
Why Exact Sciences Is Poised to Underperform [Published Motley Fool - May 03 2013]
Exact Sciences to Participate in May Investor C... [Published TradingCharts.com - May 03 2013]
Exact Sciences to Participate in May Investor C... [Published Business Wire Health News - May 03 2013]
Hot Stocks: EXACT Sciences Corporation, Hovnani... [Published SBWire - May 03 2013]
EXACT Sciences PT Raised to $14.00 (EXAS) [Published American Banking News - May 03 2013]
MADISON ? Exact Sciences? quarterly loss widens... [Published Small Business Times - May 02 2013]
Shire's Vyvanse Approved in US; Raptor's PROCYS... [Published BioMedReports - May 02 2013]
Exact Sciences Management Discusses Q1 2013 Res... [Published Healthcare Sector and Stocks Analysis from Seek ... - May 01 2013]
Exact Sciences' quarterly loss widens slightly,... [Published Individual.com - May 01 2013]
EXACT Sciences (EXAS) Announces Quarterly Earni... [Published American Banking News - Earnings - May 01 2013]
Exact Sciences Earnings: Here’s Why Investors a... [Published Wall St. Cheat Sheet - May 01 2013]
1 2 3 4 5 6
In Focus
  •  
Kevin Conroy, Peter Lawson, Jim Cramer, [more]
  •  
JPMorgan Chase & Co, Canaccord Genuity Corp, Theravance Inc, [more]
  •  
American Cancer Society, FDA Food & Drug Administration, Indiana University School of Medicine, [more]
  •  
Colorectal Cancer, polyp, Clinical trials, [more]
  •  
Xignite Financials, Pepsi, S&P 500, [more]
  •  
Madison (Wisconsin, United States), Chicago, Las Vegas (Nevada, United States), [more]
  •  
United States, Canada, United Kingdom, [more]
  •  
Diseases, Education, Research & Development, [more]
  •  
IT, Telecom, Banking & Financial Services, [more]
Business Wire Health News, EON Health & Medicine, Wall St. Cheat Sheet, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Exact Sciences Earnings: Here’s Why Investors a... [Published Wall St. Cheat Sheet - May 01 2013]
Exact Sciences Corporation ( NASDAQ:EXAS ) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 2.57%.Markets are ...
Exact Sciences Earnings: Here’s Why Investors a... [Published Wall St. Cheat Sheet - May 01 2013]
Exact Sciences Corporation ( NASDAQ:EXAS ) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 2.57%. Markets ...
Johnson & Johnson is a Buy and 4 More Analyst O... [Published Wall St. Cheat Sheet - Apr 18 2013]
Stock upgrades and downgrades are a controversial part of Wall Street. Despite regulations, many banks and firms still have a positive bias toward current clients and companies desired as future clients. In addition, Wall Street analysts are straight-up ...
Will Exact Science’s Top Institutional Sharehol... [Published Wall St. Cheat Sheet - Apr 18 2013]
Exact Sciences ( NASDAQ:EXAS ): Mizuho says that colonoscopy test screening data from Exact hit the FDA’s targets, but fell just shy of the company’s own goals which are not required for approval or commercialization. A conference call this morning has ...
Johnson & Johnson is a Buy and 4 More Analyst O... [Published Wall St. Cheat Sheet - Apr 18 2013]
Stock upgrades and downgrades are a controversial part of Wall Street. Despite regulations, many banks and firms still have a positive bias toward current clients and companies desired as future clients. In addition, Wall Street analysts are straight-up ...
1 2 3

Press Releases

sort by: Date | Relevance
Exact Sciences to Participate in May Investor C... [Published Business Wire Health News - May 03 2013]
Exact Sciences Reports First-Quarter 2013 Finan... [Published Business Wire Science: Science News - May 01 2013]
Exact Sciences Reports First-Quarter 2013 Finan... [Published Business Wire Health News - May 01 2013]
Exact Sciences to Host First-Quarter 2013 Resul... [Published Business Wire Health News - Apr 26 2013]
InVivo Enters Commercialization Phase, Adds Joh... [Published Business Wire - Apr 23 2013]
1 2 3 4 5 6
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.